Ignite Creation Date:
2024-05-06 @ 2:06 AM
Last Modification Date:
2024-10-26 @ 11:13 AM
Study NCT ID:
NCT01968213
Status:
COMPLETED
Last Update Posted:
2023-06-09
First Post:
2013-10-17
Brief Title:
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer ARIEL3
Sponsor:
pharmaand GmbH
Organization:
pharmaand GmbH
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Peritoneal Cancer |
| Ovarian Cancer |
| Fallopian Tube Cancer |
Keywords:
| Name | View |
|---|---|
| ARIEL3 | View |
| ARIEL 3 | View |
| platinum sensitive | View |
| PARP Inhibitor | View |
| rucaparib | View |
| homologous recombination | View |
| homologous recombination deficiency | View |
| CO-338 | View |
| PF 01367338 | View |
| AG 14699 | View |
| platinum sensitive ovarian cancer | View |
| platinum sensitive fallopian tube cancer | View |
| platinum sensitive primary peritoneal cancer | View |
| platinum sensitive peritoneal cancer | View |
| gynecological cancer | View |
| Clovis | View |
| Clovis Oncology | View |